-
2022-501463-40-01
5
2023-05-03
Locally Advanced or Metastatic Cholangiocarcinoma
-
2024-514080-25-00
5
2023-04-21
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
-
2024-510742-13-00
5
2023-04-19
Pediatric low-grade glioma harboring an activating RAF alteration requ
-
2024-513460-26-00
5
2023-03-29
Refractory Chronic Cough, Including Unexplained Chronic Cough
-
2024-514173-22-00
5
2023-02-28
Cystic Fibrosis
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2024-512915-33-00
5
2022-12-22
Metastatic Colorectal Cancer
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-515637-14-00
5
2022-11-08
Cystic Fibrosis
-
2023-506929-11-00
5
2022-10-17
Overweight and obesity
-
2023-507964-38-00
5
2022-09-01
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2023-506927-27-00
5
2022-08-29
Children with short stature either born small for gestational age or w
-
2024-513423-16-00
6
2022-08-25
Asthma
-
2023-509237-39-00
5
2022-08-02
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-A
-
2024-513611-28-00
4
2022-07-29
Metastatic Solid Tumors
-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2024-512378-91-00
4
2022-06-24
Unresectable or Advanced Melanoma
-
2023-505974-14-00
5
2022-06-23
Multiple Sclerosis (MS)
-
2023-505764-11-00
4
2022-06-10
Pruritus associated with Primary Sclerosing Cholangitis (PSC)
-
2023-504363-17-00
7
2022-05-13
Advanced MTAP-null solid tumors
-
2024-514723-42-00
9
2022-05-05
Locally advanced unresectable or metastatic, microsatellite instabilit
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis